CBIO Catalyst Biosciences Inc

Price (delayed)

$1.51

Market cap

$47.53M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.54

Enterprise value

$14.62M

Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Its protease engineering platform has generated ...

Highlights
CBIO's gross margin has surged by 74% year-on-year and by 17% since the previous quarter
CBIO's gross profit has surged by 71% year-on-year and by 21% since the previous quarter
Catalyst Biosciences's debt has increased by 29% YoY but it has decreased by 20% QoQ
CBIO's revenue is up by 10% year-on-year but it is down by 9% since the previous quarter
The company's equity has shrunk by 74% YoY and by 34% QoQ
CBIO's quick ratio has dropped by 65% year-on-year and by 22% since the previous quarter

Key stats

What are the main financial stats of CBIO
Market
Shares outstanding
31.48M
Market cap
$47.53M
Enterprise value
$14.62M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.75
Price to sales (P/S)
7.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.19
Earnings
Revenue
$6.67M
EBIT
-$80.03M
EBITDA
-$79.67M
Free cash flow
-$72.29M
Per share
EPS
-$2.54
Free cash flow per share
-$2.3
Book value per share
$0.86
Revenue per share
$0.21
TBVPS
$1.28
Balance sheet
Total assets
$40.27M
Total liabilities
$13.19M
Debt
$1.91M
Equity
$27.08M
Working capital
$23.51M
Liquidity
Debt to equity
0.07
Current ratio
2.78
Quick ratio
2.68
Net debt/EBITDA
0.41
Margins
EBITDA margin
-1,195.4%
Gross margin
-0.5%
Net margin
-1,200.8%
Operating margin
-1,202.7%
Efficiency
Return on assets
-115.9%
Return on equity
-149.5%
Return on invested capital
-2,336.8%
Return on capital employed
-295.5%
Return on sales
-1,200.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CBIO stock price

How has the Catalyst Biosciences stock price performed over time
Intraday
-2.58%
1 week
4.14%
1 month
12.69%
1 year
-64.55%
YTD
65.21%
QTD
128.79%

Financial performance

How have Catalyst Biosciences's revenue and profit performed over time
Revenue
$6.67M
Gross profit
-$33,000
Operating income
-$80.16M
Net income
-$80.03M
Gross margin
-0.5%
Net margin
-1,200.8%
CBIO's gross margin has surged by 74% year-on-year and by 17% since the previous quarter
CBIO's gross profit has surged by 71% year-on-year and by 21% since the previous quarter
CBIO's revenue is up by 10% year-on-year but it is down by 9% since the previous quarter
CBIO's operating income is up by 9% since the previous quarter but it is down by 7% year-on-year

Growth

What is Catalyst Biosciences's growth rate over time

Valuation

What is Catalyst Biosciences stock price valuation
P/E
N/A
P/B
1.75
P/S
7.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.19
CBIO's EPS is up by 24% year-on-year and by 11% since the previous quarter
The company's equity has shrunk by 74% YoY and by 34% QoQ
CBIO's P/B is 46% above its 5-year quarterly average of 1.2 and 35% above its last 4 quarters average of 1.3
The stock's price to sales (P/S) is 43% less than its last 4 quarters average of 12.5
CBIO's revenue is up by 10% year-on-year but it is down by 9% since the previous quarter

Efficiency

How efficient is Catalyst Biosciences business performance
CBIO's ROIC has plunged by 185% from the previous quarter
The ROE has dropped by 92% year-on-year and by 24% since the previous quarter
Catalyst Biosciences's ROA has plunged by 75% YoY and by 17% from the previous quarter
CBIO's return on sales is up by 2.7% year-on-year

Dividends

What is CBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CBIO.

Financial health

How did Catalyst Biosciences financials performed over time
CBIO's total assets has dropped by 66% year-on-year and by 28% since the previous quarter
CBIO's current ratio has dropped by 66% year-on-year and by 23% since the previous quarter
Catalyst Biosciences's debt is 93% lower than its equity
The company's equity has shrunk by 74% YoY and by 34% QoQ
Catalyst Biosciences's debt has increased by 29% YoY but it has decreased by 20% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.